Literature DB >> 21734064

Antibodies to lytic infection proteins in lymphocryptovirus-infected rhesus macaques: a model for humoral immune responses to epstein-barr virus infection.

Nina Orlova1, Mark H Fogg, Angela Carville, Fred Wang.   

Abstract

Humoral immune responses to rhesus lymphocryptovirus (rhLCV) lytic infection proteins were evaluated in the rhesus macaque animal model for Epstein-Barr virus (EBV) infection. We found a hierarchy of humoral responses to 14 rhLCV lytic infection proteins in naturally infected rhesus macaques, with (i) widespread and robust responses to four glycoproteins expressed as late proteins, (ii) frequent but less robust responses to a subset of early proteins, and (iii) low-level responses to immediate-early proteins. This hierarchy of humoral responses was similar to that reported for EBV-infected humans, with the notable exception of the response to rhBARF1. Serum antibodies to rhBARF1 were frequently detected in healthy rhLCV-infected macaques, but in humans, anti-BARF1 antibodies have been reported primarily in patients with EBV-positive nasopharyngeal carcinoma (NPC). The macaque data accurately predicted that serum antibodies against BARF1 are a normal response to EBV infection when human serum samples are analyzed. The rhesus macaque animal provides a unique perspective on humoral responses to EBV infection in humans and can be a valuable model for EBV vaccine development.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21734064      PMCID: PMC3165216          DOI: 10.1128/CVI.05126-11

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  38 in total

1.  Evaluation of an Epstein-Barr virus (EBV) immunoglobulin M enzyme-linked immunosorbent assay using a synthetic convergent peptide library, or mixotope, for diagnosis of primary EBV infection.

Authors:  D Tranchand-Bunel; H Gras-Masse; B Bourez; L Dedecker; C Auriault
Journal:  J Clin Microbiol       Date:  1999-07       Impact factor: 5.948

2.  Proteins of purified Epstein-Barr virus.

Authors:  Eric Johannsen; Micah Luftig; Michael R Chase; Steve Weicksel; Ellen Cahir-McFarland; Diego Illanes; David Sarracino; Elliott Kieff
Journal:  Proc Natl Acad Sci U S A       Date:  2004-11-08       Impact factor: 11.205

3.  Genomic sequence of rhesus cytomegalovirus 180.92: insights into the coding potential of rhesus cytomegalovirus.

Authors:  Pierre Rivailler; Amitinder Kaur; R Paul Johnson; Fred Wang
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

Review 4.  Host and viral genetics of chronic infection: a mouse model of gamma-herpesvirus pathogenesis.

Authors:  S H Speck; H W Virgin
Journal:  Curr Opin Microbiol       Date:  1999-08       Impact factor: 7.934

5.  An animal model for acute and persistent Epstein-Barr virus infection.

Authors:  A Moghaddam; M Rosenzweig; D Lee-Parritz; B Annis; R P Johnson; F Wang
Journal:  Science       Date:  1997-06-27       Impact factor: 47.728

6.  Infection of human B lymphocytes with lymphocryptoviruses related to Epstein-Barr virus.

Authors:  A Moghaddam; J Koch; B Annis; F Wang
Journal:  J Virol       Date:  1998-04       Impact factor: 5.103

7.  Detection of human serum antibodies to the BFRF3 Epstein-Barr virus capsid component by means of a DNA-binding assay.

Authors:  D Shedd; A Angeloni; J Niederman; G Miller
Journal:  J Infect Dis       Date:  1995-11       Impact factor: 5.226

8.  The BZLF1 homolog of an Epstein-Barr-related gamma-herpesvirus is a frequent target of the CTL response in persistently infected rhesus macaques.

Authors:  Mark H Fogg; Deirdre Garry; Amany Awad; Fred Wang; Amitinder Kaur
Journal:  J Immunol       Date:  2006-03-15       Impact factor: 5.422

9.  The Epstein-Barr virus (EBV) major envelope glycoprotein gp350/220-specific antibody reactivities in the sera of patients with different EBV-associated diseases.

Authors:  J Xu; A Ahmad; M Blagdon; M D'Addario; J F Jones; R Dolcetti; E Vaccher; U Prasad; J Menezes
Journal:  Int J Cancer       Date:  1998-10-23       Impact factor: 7.396

10.  First EBV vaccine trial in humans using recombinant vaccinia virus expressing the major membrane antigen.

Authors:  S Y Gu; T M Huang; L Ruan; Y H Miao; H Lu; C M Chu; M Motz; H Wolf
Journal:  Dev Biol Stand       Date:  1995
View more
  9 in total

Review 1.  Nonhuman primate models of human viral infections.

Authors:  Jacob D Estes; Scott W Wong; Jason M Brenchley
Journal:  Nat Rev Immunol       Date:  2018-06       Impact factor: 53.106

2.  Allosteric competitive inactivation of hematopoietic CSF-1 signaling by the viral decoy receptor BARF1.

Authors:  Jonathan Elegheert; Nathalie Bracke; Philippe Pouliot; Irina Gutsche; Alexander V Shkumatov; Nicolas Tarbouriech; Kenneth Verstraete; Anaïs Bekaert; Wim P Burmeister; Dmitri I Svergun; Bart N Lambrecht; Bjorn Vergauwen; Savvas N Savvides
Journal:  Nat Struct Mol Biol       Date:  2012-08-19       Impact factor: 15.369

3.  Epstein-Barr Virus gp350 Can Functionally Replace the Rhesus Lymphocryptovirus Major Membrane Glycoprotein and Does Not Restrict Infection of Rhesus Macaques.

Authors:  Marissa Herrman; Janine Mühe; Carol Quink; Fred Wang
Journal:  J Virol       Date:  2015-11-11       Impact factor: 5.103

Review 4.  BamHI-A rightward frame 1, an Epstein-Barr virus-encoded oncogene and immune modulator.

Authors:  Eveline K Hoebe; Tessa Y S Le Large; Astrid E Greijer; Jaap M Middeldorp
Journal:  Rev Med Virol       Date:  2013-08-31       Impact factor: 6.989

Review 5.  Role of BamHI-A Rightward Frame 1 in Epstein-Barr Virus-Associated Epithelial Malignancies.

Authors:  Rancés Blanco; Francisco Aguayo
Journal:  Biology (Basel)       Date:  2020-12-11

6.  Antibody Generation and Immunogenicity Analysis of EBV gp42 N-Terminal Region.

Authors:  Junping Hong; Dongmei Wei; Qian Wu; Ling Zhong; Kaiyun Chen; Yang Huang; Wanlin Zhang; Junyu Chen; Ningshao Xia; Xiao Zhang; Yixin Chen
Journal:  Viruses       Date:  2021-11-28       Impact factor: 5.048

7.  An Epstein-Barr virus encoded inhibitor of Colony Stimulating Factor-1 signaling is an important determinant for acute and persistent EBV infection.

Authors:  Makoto Ohashi; Mark H Fogg; Nina Orlova; Carol Quink; Fred Wang
Journal:  PLoS Pathog       Date:  2012-12-27       Impact factor: 6.823

8.  Gammaherpesvirus infection and malignant disease in rhesus macaques experimentally infected with SIV or SHIV.

Authors:  Vickie A Marshall; Nazzarena Labo; Xing-Pei Hao; Benjamin Holdridge; Marshall Thompson; Wendell Miley; Catherine Brands; Vicky Coalter; Rebecca Kiser; Miriam Anver; Yelena Golubeva; Andrew Warner; Elaine S Jaffe; Michael Piatak; Scott W Wong; Claes Ohlen; Rhonda MacAllister; Jeremy Smedley; Claire Deleage; Gregory Q Del Prete; Jeffrey D Lifson; Jacob D Estes; Denise Whitby
Journal:  PLoS Pathog       Date:  2018-07-12       Impact factor: 6.823

9.  Neutralizing antibodies against Epstein-Barr virus infection of B cells can protect from oral viral challenge in the rhesus macaque animal model.

Authors:  Janine Mühe; Pyone Pyone Aye; Carol Quink; Jing Ying Eng; Kathleen Engelman; Keith A Reimann; Fred Wang
Journal:  Cell Rep Med       Date:  2021-07-21
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.